<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-004816
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20071210
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20071210
<DATE-OF-FILING-DATE-CHANGE>20071210
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>071295557
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>9920 BELWARD CAMPUS DRIVE
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
<PHONE>240-268-2000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>9920 BELWARD CAMPUS DRIVE
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w44040e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Date of Report (Date of earliest event reported) December&nbsp;10, 2007</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>NOVAVAX, INC.</B>
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 40%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center" style="font-size: 8pt"><B>(Exact name of Registrant as specified in its charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware<BR>
<DIV style="font-size: 8pt">(State or other jurisdiction of incorporation or <BR>
organization)</DIV></B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770<BR>
<DIV style="font-size: 8pt">(Commission File Number)</DIV></B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046<BR>
<DIV style="font-size: 8pt">(I.R.S. Employer Identification No.)</DIV></B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>9920 Belward Campus Drive</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Rockville, Maryland</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="font-size: 8pt"><B>(Address of principal executive offices)</B></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><DIV style="font-size: 8pt"><B>(Zip Code)</B></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Registrant&#146;s telephone number, including area code:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(240)&nbsp;268-2000</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>(Former name or former address, if changed since last report.)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Pre-commencement communications pursuant to Rule&nbsp;14d-</B><B>2(b)</B><B> under the Exchange Act (17 CFR
240.14d-</B><B>2(b)</B><B>)</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Pre-commencement communications pursuant to Rule&nbsp;13e-</B><B>4(c)</B><B> under the Exchange Act (17 CFR
240.13e-</B><B>4(c)</B><B>)</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<!-- link2 "Item&nbsp;8.01 Other Events." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On December&nbsp;10, 2007, Novavax, Inc. (the &#147;Company&#148;) announced that it has entered into a
collaboration agreement with GE Healthcare, a unit of General Electric Company, to develop and
co-market a pandemic influenza vaccine manufacturing solution for selected international countries.
The collaboration will incorporate GE Healthcare&#146;s bioprocess solutions and design expertise with
the Company&#146;s virus-like particle and manufacturing platform. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit&nbsp;99.1 and is incorporated herein by
reference.
</DIV>

<!-- link2 "Item&nbsp;9.01. Financial Statements and Exhibits." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 Press release dated December&nbsp;10, 2007
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Novavax, Inc. <BR>
(Registrant) <BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">December 10, 2007&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/    Len Stigliano
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>

    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Len Stigliano                           &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>

    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer, Vice
President and Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w44040exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="w44040w4404001.gif" alt="(LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><IMG src="w44040w4404000.gif" alt="(NOVAVAX LOGO)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GE Healthcare and Novavax Establish Collaboration</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>To Develop and Market Pandemic Influenza Solution</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Collaboration aimed at enabling vaccine production facility commissioning in half the time
of a traditional egg-based facility.</I></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Once established, such a vaccine facility could allow manufacturing of pandemic flu
vaccine to commence within 12&nbsp;weeks of the strain isolation</I></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Chalfont St Giles, UK and Rockville, MD, USA: December&nbsp;10, 2007</B>
GE Healthcare, a unit of General Electric Company (NYSE: GE), and Novavax Inc. (NASDAQ: NVAX),
today announced a collaboration agreement to develop and market a pandemic influenza vaccine
manufacturing solution for selected international countries. This collaboration leverages GE
Healthcare&#146;s bioprocess solutions and design expertise and Novavax&#146;s virus-like particle (VLP)&nbsp;and
manufacturing platform.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Health planners around the world are looking to increase manufacturing capacity and vaccine
stockpiles to counter the threat of a global avian flu pandemic: the global demand for pandemic
influenza vaccine has been reported as possibly approaching 13&nbsp;billion doses, with current world
capacity at best 2.4&nbsp;billion doses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;This collaboration is a great first example of GE Healthcare realizing its strategy of enabling
affordable and safe vaccine production for countries that need to better prepare for emerging
infectious diseases,&#148; said Peter Ehrenheim, President and CEO, GE Healthcare Life Sciences.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax&#146;s VLP-based H5N1 pandemic flu vaccine is currently in Phase I/IIa clinical trials. The
goal is that any required recombinant vaccine could be produced in cell culture within 12&nbsp;weeks of
identification of a pandemic strain, without using eggs or live influenza virus &#151; as little as half
the time compared with currently available processes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Commenting on the collaboration, Dr.&nbsp;Rahul Singhvi, President and CEO of Novavax said, &#147;This
collaboration is a critical milestone in addressing one of the most pressing global healthcare
issues of the 21<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> century. We believe the combination of these technologies will enable
the creation of a country&#146;s rapid response supply and self-sufficiency in pandemic flu vaccine.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GE Healthcare&#146;s new ReadyToProcess portfolio of ready-to-use systems and devices is designed to
increase speed, simplicity and safety for all areas of bioprocessing, including the time it takes
to build and validate a facility. With Novavax&#146;s VLP and manufacturing platform, the intention is
that it could enable commissioning of a new facility from scratch in approximately two and a half
years, half the time for a traditional egg-based vaccine production facility, and at a potential
capital reduction of approximately 60 per cent.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About GE Healthcare</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GE Healthcare provides transformational medical technologies and services that are shaping a new
age of patient care. Our expertise in medical imaging and information technologies, medical
diagnostics, patient monitoring systems, performance improvement, drug discovery, and
biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new
ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to
the fullest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GE Healthcare&#146;s broad range of products and services enable healthcare providers to better diagnose
and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for
the future is to enable a new &#147;early health&#148; model of care focused on earlier diagnosis,
pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE
Healthcare is a $17&nbsp;billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare
employs more than 46,000 people committed to serving healthcare professionals and their patients in
more than 100 countries. For more information about GE Healthcare, visit our website at
www.gehealthcare.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novavax Inc</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax Inc. is a clinical stage vaccine company committed to leading the global fight against
infectious disease by creating novel, highly potent vaccines that are safer and more effective than
current preventive options. Using the company&#146;s proprietary virus-like particle (VLP)&nbsp;and Novasome&#174;
adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza,
seasonal flu and other viral diseases. Novavax&#146;s particulate vaccines closely match disease-causing
viruses while lacking the genetic material to cause disease, which provides potential for greater
immune protection at lower doses than current vaccines. With an exclusive portable manufacturing
system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet
global public health needs. Additional information about Novavax is available at www.novavax.com
and in the company&#146;s various filings with the Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Statements herein relating to future financial or business performance, conditions or strategies
and other financial and business matters, including expectations regarding product sales, operating
expenses, and clinical developments are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act. Novavax and GE Healthcare caution that these
forward-looking statements are subject to numerous assumptions, risks and uncertainties, which
change over time. Factors that may cause actual results to differ materially from the results
discussed in the forward-looking statements or historical experience include risks and
uncertainties, including the ability of Novavax and GE Healthcare to successfully market a pandemic
influenza vaccine solution; the ability of Novavax to integrate GE Healthcare&#146;s devices into its
manufacturing process; the terms and conditions of a definitive agreement with one of the selected
countries, if such an agreement is reached; uncertainties relating to clinical trials; risks
relating to the commercialization, if any, of Novavax&#146;s proposed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical
resources and patient enrollment from drug candidates in development by other companies with
greater resources and visibility, and risks that we may lack the financial resources and access to
capital to fund our operations. Further information on the factors and risks that could affect
Novavax&#146;s business, financial conditions and results of operations, is contained in Novavax&#146;s
filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These
forward-looking statements speak only as of the date of this press release, and Novavax assumes no
duty to update forward-looking statements.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B># # #</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Contact:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>GE Healthcare</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Novavax, Inc:</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Conor McKechnie
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tricia J. Richardson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">International Media Relations
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Relations Manager</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>conor.mckechnie@ge.com</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">trichardson@novavax.com</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#043;44 771 751 7028
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#043; 1 240-268-2031</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Arvind Gopalratnam</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Americas Media Relations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>arvind.gopalratnam@ge.com</U></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#043;1 414-721-2429</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w44040w4404001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w44040w4404001.gif
M1TE&.#EA40!+`.8``-73T>WLZL&]NH:!?;&NJ\W+RNGHYL;#P,C%PY&,BO+R
M\-K8U=C6T\/`OKBUL]#.S+2QKO7T\N;DX:&=FKZ[N6IE8_;V])F5DW%M:I20
MCO'P[@H(">#>V]/0S;RYM>+@W:2@GNCFY%I55#DU-*JFHGEU<TI%1&)>7(V(
MA8F%@OCX]_CX]JRHI5%-3)R8E4`\.][;V;:SL<O(Q9Z:F8)^>V1@7MS:V/KZ
M^>_N[/[__S$L+/#O[9>3D28B(NSJZ!41$CXZ.75P;J>CH5]:67QX=1T9&BTI
M*2$='8Z*B"DE)>3BX$]*21@5%38R,5U95D9"07YZ>&UH9=O9V./AX%=247=S
M<//S\>7CWH>"@/CW]NKIZ/;U]&9B8.?EXZZJJ%1/3@\,#?GY^$0_/C0O+]_=
MV^7DWTU(1G!K:#PW-RPH)Q(/$!L7%_S\_/O[^OW]_/S\^_[^_?O[^_?W]OW^
M_OW^_?KZ^OO\^_S]_/7U\R,?'_OZ^OW]_?[^_@@&!____P<%!B'Y!```````
M+`````!1`$L```?_@'Z"@X2%AH=^?(-[=6][81H:!CA688Z);(E[A8J(GI^@
MGGQLCFX^#!037$]Y/V`;?1M@/T=H%1D4``9OB71Q?'QNH</$AVQP?A($(B-%
M8'U_?QMJ:T<]14ROT-)%8T,@.&%\>^/%YH6;@GLY.8E\'!EF3+%'+247#@\&
M"G*_-V%X0@!P<*&$F2,;-OQHD0!&&W+`RIT;1H<=,#A[-!R`,D(-$S0GA!R8
M$H&.A0`P`!20@0"!C`<+0D0(8V%*@0D5@*A1@X:(@"U\Z.RY$P=BNHF&UN4`
MYH9#E1Y]U+280>8-GQLA&O`H<>*%D2-,CHP10V5($!0@*'QHPR=+&1Y._YZM
MH<%@U!MV;,@A102'31@E&%XE.1.`SQL?!6B,V!`-6I\>%198`9;##9\V'`2@
M&$!`P9[/'X@DB55BP9L[-Q1UVDNHC1L5()K$&L!`G`_%/Z+ICF9"AIPV<RB[
M2V1A1X`V2S&&^5!%S08=,R)(9.UG4\0%7]2`P0!@CPH$(ICLWMU'1X@V;'.0
MVV/!1@,!%`XLT%!GC["(;&!P8;)!1(&\;V12W5'#O!&''V[<$,,+8``Q`PY[
M%!"$$>-56,,>`;+!A@H/H&!&$TGTT$,28SQ1`Q8.`&!%40]IX0(0&S31F1N;
MP-&7.8_PL04$:_Q!10%QA`&!#K!42-X7;8CCVO\$311I9!]@C($!"UW8D4,;
M-P!@P@9%S.!(,&RL-HP*?"@`Q30#A,&&`5PD9.1X"5WP00`%B-#'-F\R!HTL
M9\BP!3E9I*!=!1:\89F8H9`3A2M>6-'&`R;<^8>D;^H&1AI-%,'8I$Y6JAL3
M-3PP2A@S(%3"#D6%LE0G$6"P01H0&.:!;)X^6>NMT:Q1@19^L`&!$6#4@,<>
M`OIA8U)6[1$!%C_T0$(8=<@PQJ:X5FOM'V"TX(`=6SB0!QA([##.9Y\9XA<?
M<3B0D!"3A?!$8]?"6RV>D^JV30\4J,"&$#_\,(,P`Q[2AB,4Y*&&"W%L:(:D
M],;KL+R-J8%"!#?P`$;_'@0,+!PG-W"P906%[>M8O;?*PH1SUBKT`[40Q[)&
M!J,,\5QA!([KQQMOG``&&EO<T$8#>5R[`084>(8'"2/4VD<:$W!`+`,5Y$8O
MI1N`<-@7?]2@P#@"CD*.&P[\D`0!&$9P1L..C>Q8#SS@L&$6<<3!;X7;;/`%
M`C?,\1`<'&#M:1('[`%!'DS$D!<R[@"S@PE_!"'.&PTD03>>E/[`0A9M?)!!
M`AID.<;D?31QQ54%("'`0Q>P3+<)%BA`PQ\C6(&A('S`\9`0,3+@!APY<-&P
MO<"_3.P#+_3Q@PQ[P"#&FSH<\(8=(/3P!Q`*M$&`ZN/=F4($&D@O1!@`$ZNL
M_Q%]@'"#'SE8T2/:TJ`\J1-;R[%E'T<LL`<"05>XP0`WQ'&%Y(W3PQX2@#WR
M;.`(`M@#",`@!AO4@79LJ`,+_I"&"-AG#RZ@U'C6X`$RB$`:1I#!'=J`!3=5
MP&<3P%X?1M"!1YSM#SH(`"3\IC0GR"$`:-A`!C91&3B$0`0;2,`XVD(%DNUF
M:&R8@AFB404<\`$&.KA3$J00AAU\D&';P,`.YL"!-)2';&R801&JU0,'N($'
M?VB!%9;R&0'\(`]2<(-EE.!%(ZGA`'PH0-#Z$+@<I&X#:[@`,%APA'K=:1L@
M((<#P,"$&:A@#TH8P^_>U(<+62$L#$A$KZ#P!R>P@?\??F@`&-Z4!QN$@0)J
M^$,1Y%`'.4#E!TA@RP[24(0H>"`*XT&`,`;`!`C(H2E++.#DF(`#-U1`AYU8
M7!\HP`<2`,`/+H"8;HX@!3XT8(Q.`$8'8)&`R5B@!FJ8`1[BL(!11F,#=?$#
M"B#0!C9HP`RPT&"E#GF!.X#@(^*H@P?R4`3+#$`)?/#=F]1`@3888`A_2`"6
MHD>"FUG@F-NKW04H)ZH]/&0/'AB!/#V%IQ<H0`(OV``9,(($J<`A`#S``Q\8
MEZ<*R.$-`!`!V=[0@0/(@0TV(`(C%\"&&RR`5HY!P!O8H@$>T,J02M--#QQR
M@C\0`!@GV``-^"``$L"!#QK_K=0:!!"&&W@U+Y<)0P&HP)@O.+0&\92%"20`
MC`@,0&J4H]N;P-``/B3@#VGB0Q.8(`0X8`$!R'C!//]PA`PHH0Z7V8-/::"&
M.QVA`6X(0!4F%0LCL$`<;F"#%8X9"S<Y#`ELH,`&AN"#-S`A#3*(@Q-"L(FF
M4G:N1JB!`\;Q`81,Z@@."$,.O&!.)A!A`3;J@`#LP`<?$($&!'``"<(SR<8`
M<F71^((;'O`#--A``AL`@@\48((5C&,"&WU3&F3X!A>8P`DND`!R5D`#XU5`
M"NC!`1:*D`0/U,X.Z]#$!,Q)MS$4`"L\D%P/]D"&'ARA``_H@PE48``TI(8/
M`$!(_W./B`4EO$$.']!"&")@@(&5P`0$P`$=<."!)?S`!"`(`!W@H(#.U:$F
M)93K#S*P*BL(8181"($.?G``#_2A!7SX@!'V0`<^R"$*X:7;#X*P`,M8H`!0
MX`$?5```MK*!`R7XE@@^\`L->.$,4:`!%H@@CTGVH0@$H!T<5,`@`^Q@!&"@
MP`1%X(<%Y`$/M--`#I7F&##H8`S\`0/R_'`#-TS!8E!*01OD(`<$)$%/\OH=
M-,!0`L5V`@)@^``>0@H!$G32#U+(0P?4X0<*Z.!6V]@&&,Q`@!O`P0TXF$`:
M$K*=-NS`#Q<H)+S2)E=H,$$&U9E##AA0!#)80`P;(("GZ?\<Z@ETE0UMP+4P
MC:2K`H1A/3N@`IY.X(,;[`$)\Y`&91.2:DHF8=3LD(`..*``&,7``W^0+@>2
ML`087-L-;4#E8&\[!`H$@`U9Z$)UNH`&W>0A!GR8PP)&(ZDC4`$%R05!"<3`
M7_T-H=!\P.$D%N.!!?S!!%O0L1J0L`4XI&:!M=J`&%@P&3:$@`=!0!\#/A<-
MD!%K`'CJ`0M\P)91M"$$9TBE$76#SCMD_`62V'$#-+"!$7P@`L7[004`L``A
M4,A3/8`9L0(@A#544A$"`.`?[+N'+DP+&FD`P`TPYP,#9`$8;>!!I\8#VCU(
MP`QAL',:'A`&^AZ@#2UP3!&^E63_;*%!"BH(T@'@'(NI^H$%8\16"%[]@!Y-
MR@N&PD$&1J"#"A2`#]P"XIO.,!D;G""/:G@"!]@`!"9,@`](F%JEU$"#+AR#
M#&<(-_V>ZH<,F-,(]<%HD?*P!4(3@5HCP*,UQ0X\$1A@#P_`PAO458,`P*%-
M1.##`2:\&S"DP/IAZ,`2A!Z-$<"`'!C8!AK8D-GKE7^H%M`VT2LP"@VTX$VD
MY8,#($`')/P!!62"!&"P!#E@`;FA-"+@&6P``&*@07TP!'$0'.\2#6@P!\'A
M?G\P!F!2`O22!G3`"R6`?SY@5]W15+'"!PB0!DQ@`7M`0Y5B!%/`%E-P!`P3
M#6`@!'[0_P9X8'E_,&2"($HV*`'$P@%%Y!@_8`$W$WO9\P=50#$5H``<@`9@
M('!^$`",PP*P5W'ZDP#B$`)(1A[3LP`(0@+4\@,!(`CSIAL5`!1PL$W;P`3%
MQP=H9"09$`97,`$8Q`1`(`R9X'^L,W,3Q@1;\P8II#\3X`@*L`244U<Y(`=-
MM2<5T`$&X`7Q-#WD4`>3I3\",`J_X`15`Q$Y`#1'H'9!,&$C4#MM4`.1UG3G
M\3,\&`U0H`!Q<`,-(!Y[H@-`(#WM,U5AX`-+8"1,4`;CH@5%<`29Y`X!$%4H
M0%7BT1CTL@2]H@`3N!MK$`,Y$`<6@#7TXE]A$`9Q@`'D1UF']/\"=>$K>8`V
M2`(,`_1C2(@^LM(':Q``&A`$E?("[*`"9.5<:T``<F0!,R!N]M('%3`9.:`!
M4"`USK@!+X!'-V`%0+!1&T`".4`';B`!P&(UA.`&67!J%Q`&`!".N\$$>+8'
M0E`$DV8"'O`9=S`X8!@-3(`%?*`>"C`DU*(&9S`%:F(!`Z"%T;!4B3`'<F<"
M'-`.Z$,N#?`#(90#*<"3T4`#86`'_N,%#J`$!P(^(#`:M@(&&6`%`))W$.`%
M2U<=?&`!X/@F4=!.;2`!_`$!Q4((V=8'&+`%!O"+&W4$[*(QGY%9,(`$$N8I
M3%`!#\"5ZO@9EZ$!#5`!6K@-:M`!H[#_`S@G!L5T""CX1@3`!AU@DL"(`@R0
M!:3`!TK@!29@3MR7$&-``PT0`0_!!G&``S)0!4900+'P!5>1`PX`%C&@288@
M!W<`!6#0`\_G!7F@.I*R`7GP!"_P+4(3DDD@!B_0!`<8::F6!@*`,Q\@6"5P
M;1B1%#>@!4NP`52``VTP`2`):6"(1?/"?:^U)_QC.T,`!B.P`^WP"X80#-#7
M)%&@`ED0`\WX,*BV;^/!!5K`!G)`!.6!`.H`#(:0`U>E`C&P!F#@`@H0!@0`
M5+O&GQ;:!!P0!G)P`6$Q`0<""F'R$!F@!D4P`?CV`##":_RIHO/2`T*5G^*!
M!!I`((<P!W70_PXYH`<)P$@H$`<J$`89`!7D.2^<$FFHM@%)L`!CZ0)@``8#
MD!Z@0`X*"@PW<)!J@`4KX%5DH#/\N09-H`.CA)[V(@9UM0<HL`92U3,(^@EB
MH@=Q,P$]8#==$!$<,`!`P)1OLF0A<!5>0(.V<D1$H`0WP"9GE@*U@SY$20P1
M804$,&M+$`-60",6```L,`1`<`3/,%`C0`([L`=7)0<?!#S.N"=H,`,!@`<'
M$)IC,`,:P!K`$!Q[T``PT@,HH)MQ@&]O\`$$,`!#H`-%X!RRL`9FD`(,P`9+
M@3YQ0(]HDQ!<P@4`P`8^$&#E85,T.A'J^`]!T"-H0`$L>#Y#Y*DW$/\`9?`!
M..!M$"$,<Q`'#'!JZ0D+!\1D1H8`BZ$&&.`#>^"CK+$)>F$?5N`!,*(&0U``
MUB&E;^"M.?!(&A(1"!("R%8A8)`$+L``-_`&'I0;,H(S4R8'U$$[ZJ$.5I`!
MDJ0&(!8`>@$!`S``/"`$`O``,!`"70`#`I``X6$O8-`$)^`"#R`'.1`!0B`"
M/U`>+A``O)`X&XL(*L``4*`31V`"/(``(8`5'4`!((`"*4`$)8`!%2`"QBD&
M+3`$4.`"N>`#86``!9``2[`&:J`#*2`#UU:M19L4P+``*$`D]$,%%W":Q'(9
M"H`#$M`%!N`#V]5SU<&:&2`"-!@Z--`!8="H!OCEMF]+"#@J"&%P`">P8W=2
M76<P`0Y0```@!1_P`60@!2K1`!<0!3H1#6I@!%P@`S=`!V&""8[[N*36#H>J
M!UV``"G`('W&!-4P(@96!*[@&&K0!"G0`!)@&8AJ!WU19++K"9L0'(*P%$3)
M!Q$```20`$20M4OP`B\@!F9`!5%0!0G@!1U`D.T@#!`Q"%?5O!OK'9*@!#!@
1`S`P!0:@`2P8D^P["($``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>w44040w4404000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w44040w4404000.gif
M1TE&.#EAWP`C`.8``$Y:AW.%I,W:Y?K\_!$E;/[Z^@\C:?K\^;G'UA$F<?[]
M]39&<JJTQ\O5W-GBZ?GY^5EFAQ(I<Q(C6FAWF!(H;",T9IJJQ$94>_7Z^>;M
M\OS[Z>KR]OW[_/W\_/[\_)>DN1$D9%9KE.3I[8B7M?[^_O3Y]_[Z]>OV]]SI
M\,',V/G[_+.\R?[]^O'S]?/V^/[^_.7T^/O]^H^=N>3Q]]+8W?'X^823J?CY
M]1(H9A`B<0X?9?K\]3I.@2@Z<OO]_OW^^O[\^/S\^/[]\OSW^J2OQA,J>",P
M6O[[\*.MO*FZS_[^^OS^_/S\_1$E>/[^]R(N9&ISB?K\\`X?6+;"SWM^C8"+
MJ!HL85YLB_WV\O[]_?;[^Q\Q9DU?E6Q^H(**GA@L:Q0H@OS^]\#4Y?CY\2\]
M9Z[!TD]ABI:<KO?[^61LD,C)SK*]U_?\_'!^EF%SF!8L<>#R]L_.V!\U<2]`
M=L+0WEUND-+>Z!8G7_/Z^N[W^7Z0K_#P])&@OQ8M?2$O;_[__R'Y!```````
M+`````#?`",```?_@#97@X-UAFXI:#\[:`-!3BPD-RN#:6EU4`Y"65DD2RQ`
M'@4'&P@R;EP\/7X4$:YO<G,`5P%)*%H',2PQ,4`/*Q"&A'5==@,<'!Y,/CZ<
M`\]98TA7PG57;30%'<Q9!0HW*=:&XFYN4V,^O+F<-&TAUH5U"$,%022B!1Y9
MS*(/*!/5W%Q9P89$%GV@'NSQ`J]:'09CH@3Q,"1&#200TES12&A$A@=`AJ@8
M("H+&P=>*HV#L,+%C1AH_L@$@*,F#A`@=.A,DP$-BP,'PD`B@4&&%`)W<&YI
ML(S$/0]!8N1),6'.%QT)$A@`8=/`5IQ<*P`@(N)`$!;]4A@!D8``3@-6__AH
MX:2,FP=>2[*(N`""@`&=4B"(R,?I!9`.&29(P4&@<=*_$V8L6?(CAH_)#@!(
MH7#3``$):5P,B&'0@VE/!SUHL:##@!00!B@8H1/CQ<$L'3K\,N*6,0$=(*1<
M0*%!`8LL,-5<V+PUJ0X_'URHX)";A`D@&VQ8R9FCNW`'&-"PT2+S#Q=7KHJH
M+Y)@"Q%<.\((??'G`1^V.#POY3"@6;X'>'Q0@00Y-&&@@1%PAD,"3>1`0`(1
M0*C#'5#0@`$+0PS!P0EF-`$&&!$V04`(>*#!"2\Q',2"$K8AL`4%6361@`1\
MJ&":/DX`<<`49-Q!01-%)$A!#F_T4`9E+Y#@P_\S-<@`0A\1/DB!%1ETH,`2
MI77RP@NFG<"%`448\$8$!)BQP9:W`;$$'E=8D4`KKA`P)@A)..&$93ZP<,,4
M5D`98G<\B%%0%LNLN,(<.H"10Q^*]H``&U'L$`-Y,G%!P:67ROD&!0;,@0(&
M0@@1Q@]8#G&&%`9\<>D3V?1W$`DH!"#%BYA&4$0.;7F%()E]]%%@!%+,(886
M]'2PQ`HZ`/G&&PU:@<)T?U"6(@L*.)%D`!+T=2L(%]!PA!*FL>#$`368\<47
MZ%UJDP0A#$#7'V'`),`%JN)4DQ0,''`$-YPX46V2=#SA6'YWT($%"TF:UH$6
M"-SQ)J:<Q:8##RUPT@'_!P68$`02!+1B8%LZ`#!#B@.HX,,&"X#P<00@&+'"
M`Z$>88('Y7&1559P1IB##B/4$(-\DY'P@`P2Q!C!4BQT$$00:.31A15>R<D9
M9Q)4+<4==TAQ=5\&WHH#!3P(4``'![FP@`%"RBB!!5IX0,(/\7;S[P9R&%"@
M@1*,T,)UW;`0!1YBW-%Q5EZ-V=C7-`S000$O*"#$#BYX`5L1'7/JA@@*N,I)
MM4XLX8,>;(49&P\GF("P4QX\(((;"[ZB0RLWZ["""C^@E;$)+51QE(.<?=8S
M=0_4$`!;66UJA0TEC`$$$"P<5_/-637F&805T*'%#Z3Z0)23"=SM1P-+<$!"
M_PQLR%"!`<I"B(,4"U21A`-PS(""&!\`<`?ZN!K`6`Y<[!%#`9VPP1>"9*L(
MX,`,&1@"">3S@WL<C`TK:%!W&G0'!RR!>2PHP"XR$`*V1*`/%(@%VB#4/0CD
M006@B,(1CA`$&GR!646`40)ZD`(E>,X@6:C6#P:`,@,PZ$U?&`$>CK.E)*D@
M"5L@`'LH``(NX,!6)`2``W:@@`,,P018W$,=)(`5$+R!`!%X0AF8P!\D;"$!
M6(D-"`(P@P-L8A\_JQG$_!(;SW`F!!L8@)*8492B=2<!WXM!![*`!A0L0`H'
M^E$.OF"&%&P``Y",P0'0X`('Z*$'!,@!Y7#PAITQ`/\#@_1!`WBPJ":X@@(5
M:``02."$>/G``QI+C`0+1`$(X"$&/S@`$)00!#:4P0IO8%`3I-"%$;B)A#FH
M0`ITZ:\C*.`(#PC!CRCW(!#(X`7'H8OI!J"%%.@@DPP"FP`>8`(M*8$$&7`#
M;"`$`C*4@0P%?)`5B'"#*!R`#;W``@<:```)N"(K8>*!"`;@`#*`0%$Y8&(=
M!.""&#CA#^F(P0[*8P:;V`0L7WN#%*:@@D'N8V@2<(M^:``*-.#!`J_I)*Y$
M!``[,*$#S7M$M6XP@#S(`&H1JDDF(8""`^S`!R[H@@$^=*D(&(`(6Q*59<AV
M`SK,H0E;L9L55A`$42UA!TK_V`$>0K"9`GUF"G:XP.LNI94)X.(%/CA`XUB0
MA#M$H`D1`P$$6G"<&P'!)!NH0ATCD`,IM`$#8W/*"Y3PAQ7T("M?D\`$:@"%
M;WX!!!30P14V`!0MI$-)`U@!&9(%I`_JP`8.D-7=(J"#'M!`!3<(`HL&:Z?G
M08\'(8B-%;[@E6X-@68^4`'1",`8"FR!!AX0`AHRP!>LL04,(*B`'7R`!2SD
M@P3<5(0&HI`!63'(@'UYPPJB,-T"3$%@.;@#NG(0@AHH(50Q.`8',#""9(F4
M`!?8P`YV4`,?1.%Q",A6)G,@5SP\X`,Z^&>#)$"')>&!#9?9`7$)8,H?-:$'
M*PC%_XWTH84&+(`]8`3#%U(PA&U,!GM+`(#=W@"U.:3`!S0()A,I``8_6$`1
M+."`ACR@@1*LH9,R6O$6N%`$"4*H!TF8+OF>@<M[N+9C(#`#`HSP,*/B0`\U
M4`$0!C`TK#3&MPWP0`<&8`<Y"(E,3<"!&[3`A`-8C`G96X)/']``*40(4VBL
M`AIN<(0#B``"!?H"8YI@X@)(L@-.X(`*9@`!'7#2+U+X@`I,$`8TH/`&B>D,
M@^_`@!O8^0YO@-*E=!"`#-R``Q$E%!^*1J:LW"$`,X-I`4JV&KL5-0$7$($)
MMNR$D70@#O=+P*9T,($31.$&`)#2UPP``)^-;30^^,$-7/]@`PEP"K(1V!1Z
M$KHV%X3A!9/!DE.<4C,9=0P'`,AK&B-+@#D@8``O8$.5R=2QI7`B"U.@0`SC
M%`$Y$.$8VU:2;3HQ@+R<X&Q"@I$.ZI"'+$QY"&M`Y-02\`4;>&`D'#`!";20
M!#+P]HL&Z$$&,!:$=:B`"%;@E`]AW9,@:`%TQ?M"`BI0!I)D80FD\0`*R.!#
M=H.`!S=X0!::QXP-7*$[8HJ`!#ZP`R`4@`DF6((*6E!H,6%%#F5``R20X(>V
MZ!DI42_`96*P!)T/8`9MD("JHGW*5I"X"WEX0'G6SG;S1(]EQ7;`'+[M0Q!<
M(0]!\,&ZK^QN3IP!!`FBM["84(#_?&OOW3[8DA;<@!4XZ^`"&2#!E`N0@3DD
ME`*=Y!;$(YX%+;3!K:UPRP3P_8(P^"(#5_!G=W)@`"1@X`'CHD,%P,BI-TB@
M"QO0Q\O_X($:3&!!N7*+&I[1O&VD8`[TSC@*HF!T)ASC`=]MT.#J@((;Y"@S
M;'D#VB10AXUW8C),"/\#''`!M^H:8A&X0QT<\`"UM[WM-LN*`0&`!Q\(D+<J
M0PH"F+'W=C<`-UD@.0E%;SQ@!_?`"4[A`W^0&EC"`B6@5[PC<,/1.`-0`%K0
M;)CB&3C@`-V0#RKP;UX$(00`82H`70Y514G0`SB@'DV@`W.P!T!P!!IP!"X`
M`1+P-0\S_P=30`)HT0E94`-),'LY8%040`!4,!+-8P)LH!W%XQ9C9F8'P09!
M@`%ID`!@T!84@"]:$`1'H$\CD"T1\@8XH$RZX!0_L"1,@`4F@``\T&,Q5!.M
MP`,I\```]'[P=S.4<P%:0'E<]46$PP,.$`3]AV6=X`-4@`,#2"81,!P1QX.<
MH(`YXC8YM`,C``*7)W"`:!AL0$8.8`0P<GD&X`5[R`'AEP0@0#D%`@)N<`+V
M@`:ZQ`(UP!>`)R/'LP]9$`3+0`=6L"A$PD0AD"=C8QLDX'-2T!9^T01DX`#:
MPP(FD`<+D$F>46Y3`!0^P`0/YP-T<`=@("-H1#$(A@Q,(``\0/\`V[AI7,`&
MS),%.R1Y6$0'/(`>!E03$<`%=N`"&6.';!=_"1`F`(`&)N`#9?`$0W(S!*`'
M`^`",J`#?6!'?<<$5`!X<`)&/(`"&7-;C_@'D6@01[`#-J`R<&8`"^``AO$,
M'>`"4&!^19@#D$</*E`#=0`C^W4';*,`7#<`0(`!:R`XG)(`(+``#5``0)E!
M'(`'8L57$<)P#G`#08DQ#X`$@L-N36`%2=!12Y.-?/5$@;$!GE.-'L`!(M`&
M.&!*KJ`#%C`V&%,`0]`"(R`%BG(I.8`##9!S]6"3)H`%>0`!C-$6<'439!(`
M:8<%?T`"3$`"^&@IET(Y_7@$PZ@';O;_(+?2`PTP-&P!(X38"6?P1!$9`0L@
M`!CS;DKR!Z#@-JR$!A-@B96#1A<P`P;'#"RP`VH@`3[4&%&)`,A``@+0`ZY@
M-P0@1:QT`-HF`F:`%3IU!T+$"3#7#2I@`4\0EA`2(5"0=O5P$!V0&?GAF"!0
M!WA@DVC0!9880TAA`=K#"]WP"Q7P-4]D`(!H$-68&P]@!^>34-'3!AM7`#^`
M!D%@`ALP/"#P6&#B%Y:8`%:@!VT3F`AHAX8I;[N)!D>0!2I@!YB424!B`&T@
M`I7(>OZ'@"NP()DI!PQ0@<F0@`MH&HD'!"4@5@\C<";4`5/V,U'@`A<P<IF$
M`P$P'1WP`1YD_S<TX@)98!8DP!]M]2`U\05;H`<,4*1&6J1\,`?$0T+5\P`8
MXP$QY@)GX&R$(QLH,`!*X``+(&]:80#=<@!O4SL%L`<3<`<VT3%<0`1'R@`K
MH*9S@(@/TCUDP%&=H#0E\`%)Q!E]X1=^L8\KAP`J$)@&T0$&FB!*E*#[,@0/
MT`;%""1:(0<(<!\66IE,0`<JEYE/Y@-#P`2=H"0XM`_8E`$5$&".MU@=H`3X
M%`5.X`-54(2Y$@&D,P198`91@FAV<!P^4'B@%@(ZP!YP."&PV1A^H1-N"#TL
M4P4JD`7)T)4#0`.;L8^Q(07G!@0(<$P!I@-5T`(W\`=*8"<>8&&/]?\U1=@9
M46,W=X.*N)(`4E`%;*`X+*`",\<6_@D"L'DK$$IL(L!M!E&H11@A`(`!)C``
M&?(!!-($?>`7.(`$?*`#"76AA"(`<I"(8(0#HR>KVY9XB(<E`F`$L>%X58`'
MIYJJJ_H!?@!&?D$!&I<A<Q!,GF$`1J":G9`/!=`"<W<KG*%]6J,3.JNSFF2L
M<E4#'=B5*I`!`F,K12@%1/``"D`$OJ&09%D".T`"2J``"L`!#%`!3"2N.+&S
M7(LK^_4@4I`&>8`&'``$-=`P"](Q.B`%%<`6#M(];Y!*@RFH_"IO.4!_"L`&
M,K87!?*&17`!53"9%WHQ&4!*F=E.+?``)1C_F#Z@!-\W`#\@I<58.0)G`350
MMCZ`!F$0!5S&`Q#"*<.$``40!\58!'O:!G@@<2I`#T.P`N;Z)L"7(.EJC#K!
MI[C2"CE@!0WP2MDT$HP7)%Z$`U`@`DX0G`<K(5>Z2DX0*EE0!QF%+DS$8`ZB
M4ZMG:$/".SE`!HD0<31P`>)J*Z65`EQ0(&VQ+1>@<_A8*=`3,EK@+E'!`7&@
M<F^B+7+`&590$TOQ3#>`!^T%)$-8$Q+@!AG@`C)&#QGC.&&@!5>;'UI1A,3F
M``/`<PQD0\VF/PY#3"A0!<Y&-5N0`@5P5T$`!#?@`&;P;9`%(^L!/2K,(`["
ML'W5!0FD)+S@`RG@_P?2UQU/@``-<#\3!`)M@`8[P`;HJ`UQX!5V)"=B(D,K
MG!5Z!CNF"P$WH`%V$)R4(TQ?@`!K.`?=(ZQ;T0:W4+;YP`P*J+XRPE?T9XVJ
M]@"LPU?1VQ9P2`"!!`1!H`(.T`/)HDF0!0)64`SV")1`>0`ED`$6P`/$$R%J
M]`$U``HLD&S8@VTI0`;:]S5?L`!)``"8-ZP(Y!/WB04J\`$,;%3&F!.M8<2D
M[!56]B`[,Z?&&0-!\`,9``#)TA8[,P)$TTD,L@4(<`,_)64SFP9>,;NF/,JE
M;,1P>)0$\`0"T`)/H\3\504N@!T6(#BYXA5;(`,GP`1&MP_-\#QE?+>WU/^5
M+Z`Q<?",W5$3W\1;61%(U*@"`6`%#-;`%/`%4@``%B``)Y`')7`"<%`&7;`%
M8'*[KH`#"Y`!NF0<))`DVQ9IG()Y351U.J,#2"#$/Z,`E"=B\L<>/6`&`+#1
M'-W1',T#C!$D;7$'79#(XF(GJU&,K->"/$`37^0*\74#"N`4&D,':V$W,N('
M+>W1/`T`(*U];V54`<"T7+P5`TV3/`0!\BJL`@VH-Z!['4`S,F$&,.(*WJP`
M1K=+J\H'=]`'8;:3@P-(#<`"&,#*?Y`!=>`PWOD&^ZDU$M`#"[``/6`%V6*N
M88(N!%`!^P<$5!L)"&@0`Y`"(0556($K?1`DG8+_`9;%!H;A`A^PBP%&.2`@
M!C6``=0HQIC-#`V`M6_R1>V$`,QC)PK@`R>P62S38V\)&WJ*!`]P`Q+'`0X(
M!3@A0P3@!L^B`B:3V9@]+[UUJ')@!;?2LA1@;C"C!9*DI9G4&!`B`63P+.\&
MI10%)U\$`"5P7Y'`UT!@![`,O.9:A`3P6T"`!B70/"K`3ZCR,(W!'H1C-UC8
M%P&F/WJ<!"7`USFB!$J`#&[#`DS@C`52KGQ5!!,2`$>W)(L,@@:$9/2'15B$
M/0S>X#]P`A/@;*K2/:KH`5MB)V0=`)BY*`D@KI\Q!Q7#C(*I`@+@5JIR*1*P
M`J^G90[NX,)S@WLE)@;2_Z<@,`)YL`1YZTP/4`9]<3,)(@%7$'D[%PG<'"?T
MER-GV`SOJHMOU3WD^R:L8CH(#5WYZ<\CUST?LQ4?XZK]36Q3L(<(XSDOX`2F
MP0EHX0-$<`<SCA/2VY-QH&5.H00U8`%H@RDXL`5(0`(KI`#(@2)^S@L*(`#N
MO&<&`@(TH'=,\`('H`5BL`!9L7I8W@2G]C9*0"I:(`(3D"C[:$`+P`949"U_
M_N<L\,C529`@$B$Z`,.\H`7=:B=+H`?C=8HY%0`U<!U!,``U`W2_`0!:\`+:
MP"]H``,1WABKAV2LLG,OQPP',``90`1F(`?K="`R<C?<Z""3K`<"\'K,DU[]
MX?^X9MX-T[D`:50UQ.-7&\"#W9JEX_@;AB8%9N``L&0"H.;']$[O>1"<-2%!
M(``%+6`R.ZH%&]`%*JT3YNJ""+`$2?("DZ)9EM@=GV$!3-`\'I"K]4[O)E!=
M4B#,]&JA+B@`0.P$Z(@]=N(`';05#!(D5L``+M`!!X`'Y0$!3Q#S,0\`'/`"
M_-$,_(8!=$`&1E`!6^`'?E`!%6`$9$`#W3#Q_1$$V*8%*&`!$T`&7/1-QO@7
MP''G/#`"=%`"9O8`V/0,_5$9GW`<9&.2/3_T1F`$6[`%9)`$>L1:/\``/1_S
M5C#T']`V0&DLR)#W>H\Q&&`!//\$:;\%1$\#G+H,6L#_!@Q`!A4@\UOP!'[P
M!&A'&@81`QC@!7'_!3%_`0XP-OH0/GNO]PJ``6IA!#'?^*3_!$)O`8MV!'="
M1/YR``A`!E?!8$!"``N0`A@@Q.5Q`C"P`3```S.P`3$0!9;A]LN.&+S_^[\/
M!S``!R5@`F.CS1(E*6@`22=@!T00`&Z@T0#`!5S0!7P@!BA0`VR@`CO00#Q(
M*NG%"Z.1CL@P!'C`_,K?_,"/!R5PT"]`*GD`!\P/"#,G)S,8+QZ(64LQC(V.
M0RIX,S!PE7`G&2X<!5EH,0=:,W`;&S`PA#,;/SY9K6$#I:>F,WEH#QQ9)"2.
MO#%'!V@PL::GE84<'4IA,1Y9_R]*3CLE95(1$3G7!G<`=G@'?^`_+"Q.`RH_
M0AIH3$#IRP]8)AP_'@5#+$L#/B0:!04<N]`<V"%$B!,E"%_$&%#"10L7#YB0
M^)-KP(`#2W21^/'BA\<!;`XH`$(B"[(#`PJP^,&(28<_+':T\K%DR3Y<3+1H
M&?``B)(7&GLY4@GD1JX8.W8HR.-CR#\2"A2\Z"".`Q,?6/RQT+"D`R(G&-B(
M?7`@QH\;,?:5+""TT1$G_OQUR.+5*I,'0SR`''#(P\H?"L*<Z)(C00("!"*\
MN7,%@P)PD"-+GDRYLN7+F#-KWLRYL^?/H#?[\^MDE0\1%T#@,&"``#80>EID
M&;`DM'3MV[ASZ][-.S,BTC'RJ8C3@P`%`Q0B''Y"9$`0%KVC2Y].O;KG5ED0
M!HFAPH<*/5:^@/CRQK"..0X.3+3.OKW[]Z!?R.<8@P6)%[`F2,"A^LTU'0`X
A4!M\!!9HH'L>R:?+"]$X<40*"X!`@`ZM)99#`'@$`@`[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
